Broadcast Date: November 21, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Delivering efficacious therapeutic candidates involves screening your entire panel to understand their kinetic and epitope profiles while understanding each candidate’s relationship relative to others. In combination with other data such as antibody sequences and epitope mapping, high throughput epitope binning and kinetic screens enable fast and optimized selection of antibody panels for mechanism of action select MOA) studies, while simultaneously providing a crucial evaluation of antibody generation technologies.
In this GEN webinar, we will demonstrate how modern-day high-throughput surface plasmon resonance select HT-SPR) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This new paradigm combines screening and detailed characterization in the same step, condensing months of work into days.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Zimple Matharu, PhD
Scientist
Bristol-Myers Squibb
